<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00365625</url>
  </required_header>
  <id_info>
    <org_study_id>244/06</org_study_id>
    <nct_id>NCT00365625</nct_id>
  </id_info>
  <brief_title>Determination of Lymphocyte JAM-C Expression in Patients With Psoriasis Vulgaris</brief_title>
  <official_title>Patient Orientated Basic Science Investigation: Determination of Lymphocyte JAM-C Expression in Patients With Psoriasis Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <brief_summary>
    <textblock>
      The stepwise process of leukocyte extravasation to inflamed tissues depends on the expression&#xD;
      of a variety of cytokines and adhesion molecules. Recently much attention has focused on the&#xD;
      Junctional Adhesion Molecules (JAM). The three members of this adhesion molecule family,&#xD;
      namely, JAM-A, -B and -C, have been shown to govern the last step of leukocyte extravasation&#xD;
      (transmigration) - the process of leukocytes passing between endothelial cells. In addition&#xD;
      to transmigration, some members of this family seem to support additional steps in the&#xD;
      leukocyte extravasation cascade. The investigators recently showed, that antibody-mediated&#xD;
      inhibition of JAM-C significantly reduced hapten induced skin inflammation (J Invest&#xD;
      Dermatol;125(5):969).&#xD;
&#xD;
      Recent unpublished work from our laboratory showed, that JAM-C expression of lymphocytes can&#xD;
      be up-regulated through specific activators. Hence, the investigators hypothesize, that JAM-C&#xD;
      expression is elevated in patients with psoriasis. As it is currently not know, which factors&#xD;
      may influence the expression of JAM-C, the investigators intend to analyse JAM-C expression&#xD;
      on CD3+CD41- cells at several time-points during the treatment of psoriatic patients.&#xD;
      Expression of JAM-C will then be correlated to disease activity (PASI).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The stepwise process of leukocyte extravasation to inflamed tissues depends on the expression&#xD;
      of a variety of cytokines and adhesion molecules. Recently much attention has focused on the&#xD;
      Junctional Adhesion Molecules (JAM). The three members of this adhesion molecule family,&#xD;
      namely, JAM-A, -B and -C, have been shown to govern the last step of leukocyte extravasation&#xD;
      (transmigration) - the process of leukocytes passing between endothelial cells. In addition&#xD;
      to transmigration, some members of this family seem to support additional steps in the&#xD;
      leukocyte extravasation cascade. We recently showed, that antibody-mediated inhibition of&#xD;
      JAM-C significantly reduced hapten induced skin inflammation (J Invest Dermatol;125(5):969).&#xD;
&#xD;
      Recent unpublished work from our laboratory showed, that JAM-C expression of lymphocytes can&#xD;
      be up-regulated through specific activators. Hence, we hypothesize, that JAM-C expression is&#xD;
      elevated in patients with psoriasis. As it is currently not know, which factors may influence&#xD;
      the expression of JAM-C, we intend to analyse JAM-C expression on CD3+CD41- cells at several&#xD;
      time-points during the treatment of psoriatic patients. Expression of JAM-C will then be&#xD;
      correlated to disease activity (PASI).&#xD;
&#xD;
      Detailed in- and exclusion criteria are outlined below.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2005</start_date>
  <completion_date type="Anticipated">December 2007</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Psoriasis</condition>
  <condition>Psoriasis Vulgaris</condition>
  <eligibility>
    <study_pop>
      <textblock>
        psoriasis patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Psoriasis vulgaris&#xD;
&#xD;
          -  PASI &gt;/= 10 at inclusion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Psoriasis arthritis&#xD;
&#xD;
          -  Psoriasis pustulosa&#xD;
&#xD;
          -  Psoriasis palmoplantaris&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  current infectious disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralf J Ludwig, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Dermatology - Clinic of the Johann Wolfgang Goethe University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roland Kaufmann, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Dermatology - Clinic of the Johann Wolfgang Goethe University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wolf-Henning Boehncke, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Dermatology - Clinic of the Johann Wolfgang Goethe University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ralf J Ludwig, MD</last_name>
    <phone>0049-69-6301-</phone>
    <phone_ext>6162</phone_ext>
    <email>r.ludwig@em.uni-frankfurt.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wolf-Henning Boehncke, Professor</last_name>
    <phone>0049-69-6301-</phone>
    <phone_ext>5743</phone_ext>
    <email>boehncke@em.uni-frankfurt.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Dermatology - Clinic of the Johann Wolfgang Goethe University</name>
      <address>
        <city>Frankfurt Am Main</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralf J Ludwig, MD</last_name>
      <phone>0049-69-6301-</phone>
      <phone_ext>6162</phone_ext>
      <email>r.ludwig@em.uni-frankfurt.de</email>
    </contact>
    <contact_backup>
      <last_name>Wolf-Henning Boehncke, Professor</last_name>
      <phone>0049-69-6301-</phone>
      <phone_ext>5743</phone_ext>
      <email>boehncke@em.uni-frankfurt.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Ludwig RJ, Zollner TM, Santoso S, Hardt K, Gille J, Baatz H, Johann PS, Pfeffer J, Radeke HH, Sch√∂n MP, Kaufmann R, Boehncke WH, Podda M. Junctional adhesion molecules (JAM)-B and -C contribute to leukocyte extravasation to the skin and mediate cutaneous inflammation. J Invest Dermatol. 2005 Nov;125(5):969-76.</citation>
    <PMID>16297198</PMID>
  </reference>
  <reference>
    <citation>Santoso S, Sachs UJ, Kroll H, Linder M, Ruf A, Preissner KT, Chavakis T. The junctional adhesion molecule 3 (JAM-3) on human platelets is a counterreceptor for the leukocyte integrin Mac-1. J Exp Med. 2002 Sep 2;196(5):679-91.</citation>
    <PMID>12208882</PMID>
  </reference>
  <reference>
    <citation>Chavakis T, Keiper T, Matz-Westphal R, Hersemeyer K, Sachs UJ, Nawroth PP, Preissner KT, Santoso S. The junctional adhesion molecule-C promotes neutrophil transendothelial migration in vitro and in vivo. J Biol Chem. 2004 Dec 31;279(53):55602-8. Epub 2004 Oct 14.</citation>
    <PMID>15485832</PMID>
  </reference>
  <reference>
    <citation>Muller WA. Leukocyte-endothelial-cell interactions in leukocyte transmigration and the inflammatory response. Trends Immunol. 2003 Jun;24(6):327-34. Review.</citation>
    <PMID>12810109</PMID>
  </reference>
  <reference>
    <citation>Vonlaufen A, Aurrand-Lions M, Pastor CM, Lamagna C, Hadengue A, Imhof BA, Frossard JL. The role of junctional adhesion molecule C (JAM-C) in acute pancreatitis. J Pathol. 2006 Aug;209(4):540-8.</citation>
    <PMID>16767690</PMID>
  </reference>
  <reference>
    <citation>Santoso S, Orlova VV, Song K, Sachs UJ, Andrei-Selmer CL, Chavakis T. The homophilic binding of junctional adhesion molecule-C mediates tumor cell-endothelial cell interactions. J Biol Chem. 2005 Oct 28;280(43):36326-33. Epub 2005 Aug 23.</citation>
    <PMID>16118203</PMID>
  </reference>
  <reference>
    <citation>Lamagna C, Hodivala-Dilke KM, Imhof BA, Aurrand-Lions M. Antibody against junctional adhesion molecule-C inhibits angiogenesis and tumor growth. Cancer Res. 2005 Jul 1;65(13):5703-10.</citation>
    <PMID>15994945</PMID>
  </reference>
  <reference>
    <citation>Aurrand-Lions M, Lamagna C, Dangerfield JP, Wang S, Herrera P, Nourshargh S, Imhof BA. Junctional adhesion molecule-C regulates the early influx of leukocytes into tissues during inflammation. J Immunol. 2005 May 15;174(10):6406-15.</citation>
    <PMID>15879142</PMID>
  </reference>
  <verification_date>August 2009</verification_date>
  <study_first_submitted>August 16, 2006</study_first_submitted>
  <study_first_submitted_qc>August 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2006</study_first_posted>
  <last_update_submitted>February 1, 2010</last_update_submitted>
  <last_update_submitted_qc>February 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. Ralf Ludwig</name_title>
    <organization>Johann Wolfgang Goethe University Hospitals</organization>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <keyword>JAM3 protein, human</keyword>
  <keyword>Cell Adhesion Molecules</keyword>
  <keyword>Skin</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Lymphocytes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

